• +32 3 369 17 40
  • info@etherna.be
Linkedin Twitter Facebook Youtube
  • Company
    • About
    • U.N. SDG Commitment
    • Management Team
    • Board of Directors
    • Shareholders
    • Strategic Collaborations
    • Key Milestones
    • Quick facts
  • Platforms
    • 3 Platforms
    • Partnership
  • Manufacturing
  • News and Events
    • Press releases
    • Press information
    • Conferences
    • Webinars
  • Careers
  • More info
    • Scientific papers
    • Factsheets
    • Photos
    • Videos
    • Contact Us
Menu
  • Company
    • About
    • U.N. SDG Commitment
    • Management Team
    • Board of Directors
    • Shareholders
    • Strategic Collaborations
    • Key Milestones
    • Quick facts
  • Platforms
    • 3 Platforms
    • Partnership
  • Manufacturing
  • News and Events
    • Press releases
    • Press information
    • Conferences
    • Webinars
  • Careers
  • More info
    • Scientific papers
    • Factsheets
    • Photos
    • Videos
    • Contact Us
// Stay up to date

Press releases

Follow our progress in developing products that have the potential to transform the future of cancer treatment.

Archive 2022
Archive 2021
Archive 2020
Archive 2019
Archive 2018
Archive 2017
Archive 2016

2020

// 15 DECEMBER 2020

eTheRNA immunotherapies & Frame Therapeutics are awarded EUR 1.9 million Eurostars research grant for their novel cancer vaccine collaboration

// 1 DECEMBER 2020

eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focused on eTheRNA’s proprietary mRNA development products and manufacturing capabilities

// 3 NOVEMBER 2020

eTheRNA extends mRNA contract manufacturing services

// 8 OCTOBER 2020

eTheRNA extends senior management team with appointment of Michael Mulqueen as VP Business Development

// 16 JUNE 2020

eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through to clinical proof of concept

// 22 APRIL 2020

Frame Therapeutics and eTheRNA immunotherapies NV open a new research collaboration to develop mRNA cancer vaccines against immunogenic neoantigens

// 24 MARCH 2020

eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine for High Risk Populations

Galileilaan 19, 2845 Niel, Belgium

Our Address

info@etherna.be

Our Mailbox

+32 3 369 17 40

Our Phone
  • Privacy Policy
  • Terms of Use
  • Contact Us
Menu
  • Privacy Policy
  • Terms of Use
  • Contact Us

© 2022 eTheRNA | Studio Hanswijk

Twitter Linkedin-in Facebook Youtube
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non Necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Save & Accept